Global Meropenem Market
Global Meropenem Market

Meropenem Comprehensive Study by Application (Hospital use, Clinic, Others), Distribution Channel (Online, Offline), Strength (0.5g, 1.0g, 1.5g, 2.0g) Players and Region - Global Market Outlook to 2024

Meropenem Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 246 Pages 186 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Meropenem Market Overview:
Meropenem is a carbapenem antibiotic, which is active against gram-positive and gram-negative bacteria. Meropenem penetrate bacterial cells by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem injection does not work for cold, flu or other viral infections. Taking antibiotics when they are not needed increases the risk of getting an infection which afterwards resists antibiotic treatment. Meropenem is an important option for the empirical treatment of serious bacterial infections in hospitalized patients. Some of the key players profiled in the study are Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States).

On the basis of geography, the market of Meropenem has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Spain, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strength, the sub-segment i.e. 0.5g will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing awareness towards healthy lifestyle
  • Rising prevalence of skin infection across the globe

Market Trend
  • Growing use in empirical treatment
  • Effective in the treatment of bacterial meningitis

Restraints
  • Inappropriate use can affects adversely

Opportunities
  • Increasing healthcare infrastructure in developing countries

Challenges
  • Easy availability of substitutes


March 20, 2019: Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics and On 7th Jan 2019 Takeda has acquired Shire


The companies are exploring the market by adopting mergers & acquisitions, expansions and investments as their preferred strategies. Key players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations.

Target Audience:
Manufacturers of pharmaceutical drugs, Suppliers of pharmaceutical drugs, Wholesalers, distributers and retailers of pharmaceutical drugs, Healthcare industry, Research Firms and Governmental bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Meropenem market on the basis of product [] , application [Hospital use, Clinic and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Meropenem market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Spain, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Meropenem industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Spectrum Chemical Manufacturing Corp (United States), Shijiazhuang Pharma (China) and Haikou Pharmaceutical Factory (China).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Meropenem market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Application
  • Hospital use
  • Clinic
  • Others
By Distribution Channel
  • Online
  • Offline

By Strength
  • 0.5g
  • 1.0g
  • 1.5g
  • 2.0g

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Spain
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing awareness towards healthy lifestyle
      • 3.2.2. Rising prevalence of skin infection across the globe
    • 3.3. Market Challenges
      • 3.3.1. Easy availability of substitutes
    • 3.4. Market Trends
      • 3.4.1. Growing use in empirical treatment
      • 3.4.2. Effective in the treatment of bacterial meningitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meropenem, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Meropenem (Value)
      • 5.2.1. Global Meropenem by: Application (Value)
        • 5.2.1.1. Hospital use
        • 5.2.1.2. Clinic
        • 5.2.1.3. Others
      • 5.2.2. Global Meropenem by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Offline
      • 5.2.3. Global Meropenem by: Strength (Value)
        • 5.2.3.1. 0.5g
        • 5.2.3.2. 1.0g
        • 5.2.3.3. 1.5g
        • 5.2.3.4. 2.0g
      • 5.2.4. Global Meropenem Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Spain
          • 5.2.4.3.6. Netherlands
          • 5.2.4.3.7. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Meropenem (Volume)
      • 5.3.1. Global Meropenem by: Application (Volume)
        • 5.3.1.1. Hospital use
        • 5.3.1.2. Clinic
        • 5.3.1.3. Others
      • 5.3.2. Global Meropenem by: Distribution Channel (Volume)
        • 5.3.2.1. Online
        • 5.3.2.2. Offline
      • 5.3.3. Global Meropenem by: Strength (Volume)
        • 5.3.3.1. 0.5g
        • 5.3.3.2. 1.0g
        • 5.3.3.3. 1.5g
        • 5.3.3.4. 2.0g
      • 5.3.4. Global Meropenem Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Spain
          • 5.3.4.3.6. Netherlands
          • 5.3.4.3.7. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Meropenem (Price)
  • 6. Meropenem: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shenzhen Haibin Pharmaceutical (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fresenius Kabi (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sumitomo Pharmaceuticals (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sumitomo Dainippon Pharma Co. Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astra Zeneca Pharma (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GE Healthcare (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Meropenem Sale, by Application, Distribution Channel, Strength and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Meropenem (Value)
      • 7.2.1. Global Meropenem by: Application (Value)
        • 7.2.1.1. Hospital use
        • 7.2.1.2. Clinic
        • 7.2.1.3. Others
      • 7.2.2. Global Meropenem by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Offline
      • 7.2.3. Global Meropenem by: Strength (Value)
        • 7.2.3.1. 0.5g
        • 7.2.3.2. 1.0g
        • 7.2.3.3. 1.5g
        • 7.2.3.4. 2.0g
      • 7.2.4. Global Meropenem Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Spain
          • 7.2.4.3.6. Netherlands
          • 7.2.4.3.7. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Meropenem (Volume)
      • 7.3.1. Global Meropenem by: Application (Volume)
        • 7.3.1.1. Hospital use
        • 7.3.1.2. Clinic
        • 7.3.1.3. Others
      • 7.3.2. Global Meropenem by: Distribution Channel (Volume)
        • 7.3.2.1. Online
        • 7.3.2.2. Offline
      • 7.3.3. Global Meropenem by: Strength (Volume)
        • 7.3.3.1. 0.5g
        • 7.3.3.2. 1.0g
        • 7.3.3.3. 1.5g
        • 7.3.3.4. 2.0g
      • 7.3.4. Global Meropenem Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Spain
          • 7.3.4.3.6. Netherlands
          • 7.3.4.3.7. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Meropenem (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meropenem: by Application(USD Million)
  • Table 2. Meropenem Hospital use , by Region USD Million (2013-2018)
  • Table 3. Meropenem Clinic , by Region USD Million (2013-2018)
  • Table 4. Meropenem Others , by Region USD Million (2013-2018)
  • Table 5. Meropenem: by Distribution Channel(USD Million)
  • Table 6. Meropenem Online , by Region USD Million (2013-2018)
  • Table 7. Meropenem Offline , by Region USD Million (2013-2018)
  • Table 8. Meropenem: by Strength(USD Million)
  • Table 9. Meropenem 0.5g , by Region USD Million (2013-2018)
  • Table 10. Meropenem 1.0g , by Region USD Million (2013-2018)
  • Table 11. Meropenem 1.5g , by Region USD Million (2013-2018)
  • Table 12. Meropenem 2.0g , by Region USD Million (2013-2018)
  • Table 13. South America Meropenem, by Country USD Million (2013-2018)
  • Table 14. South America Meropenem, by Application USD Million (2013-2018)
  • Table 15. South America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 16. South America Meropenem, by Strength USD Million (2013-2018)
  • Table 17. Brazil Meropenem, by Application USD Million (2013-2018)
  • Table 18. Brazil Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 19. Brazil Meropenem, by Strength USD Million (2013-2018)
  • Table 20. Argentina Meropenem, by Application USD Million (2013-2018)
  • Table 21. Argentina Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 22. Argentina Meropenem, by Strength USD Million (2013-2018)
  • Table 23. Rest of South America Meropenem, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 25. Rest of South America Meropenem, by Strength USD Million (2013-2018)
  • Table 26. Asia Pacific Meropenem, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Meropenem, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 29. Asia Pacific Meropenem, by Strength USD Million (2013-2018)
  • Table 30. China Meropenem, by Application USD Million (2013-2018)
  • Table 31. China Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 32. China Meropenem, by Strength USD Million (2013-2018)
  • Table 33. Japan Meropenem, by Application USD Million (2013-2018)
  • Table 34. Japan Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 35. Japan Meropenem, by Strength USD Million (2013-2018)
  • Table 36. India Meropenem, by Application USD Million (2013-2018)
  • Table 37. India Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 38. India Meropenem, by Strength USD Million (2013-2018)
  • Table 39. South Korea Meropenem, by Application USD Million (2013-2018)
  • Table 40. South Korea Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 41. South Korea Meropenem, by Strength USD Million (2013-2018)
  • Table 42. Taiwan Meropenem, by Application USD Million (2013-2018)
  • Table 43. Taiwan Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 44. Taiwan Meropenem, by Strength USD Million (2013-2018)
  • Table 45. Australia Meropenem, by Application USD Million (2013-2018)
  • Table 46. Australia Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 47. Australia Meropenem, by Strength USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Meropenem, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Meropenem, by Strength USD Million (2013-2018)
  • Table 51. Europe Meropenem, by Country USD Million (2013-2018)
  • Table 52. Europe Meropenem, by Application USD Million (2013-2018)
  • Table 53. Europe Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 54. Europe Meropenem, by Strength USD Million (2013-2018)
  • Table 55. Germany Meropenem, by Application USD Million (2013-2018)
  • Table 56. Germany Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 57. Germany Meropenem, by Strength USD Million (2013-2018)
  • Table 58. France Meropenem, by Application USD Million (2013-2018)
  • Table 59. France Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 60. France Meropenem, by Strength USD Million (2013-2018)
  • Table 61. Italy Meropenem, by Application USD Million (2013-2018)
  • Table 62. Italy Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 63. Italy Meropenem, by Strength USD Million (2013-2018)
  • Table 64. United Kingdom Meropenem, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 66. United Kingdom Meropenem, by Strength USD Million (2013-2018)
  • Table 67. Spain Meropenem, by Application USD Million (2013-2018)
  • Table 68. Spain Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 69. Spain Meropenem, by Strength USD Million (2013-2018)
  • Table 70. Netherlands Meropenem, by Application USD Million (2013-2018)
  • Table 71. Netherlands Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 72. Netherlands Meropenem, by Strength USD Million (2013-2018)
  • Table 73. Rest of Europe Meropenem, by Application USD Million (2013-2018)
  • Table 74. Rest of Europe Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 75. Rest of Europe Meropenem, by Strength USD Million (2013-2018)
  • Table 76. MEA Meropenem, by Country USD Million (2013-2018)
  • Table 77. MEA Meropenem, by Application USD Million (2013-2018)
  • Table 78. MEA Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 79. MEA Meropenem, by Strength USD Million (2013-2018)
  • Table 80. Middle East Meropenem, by Application USD Million (2013-2018)
  • Table 81. Middle East Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 82. Middle East Meropenem, by Strength USD Million (2013-2018)
  • Table 83. Africa Meropenem, by Application USD Million (2013-2018)
  • Table 84. Africa Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 85. Africa Meropenem, by Strength USD Million (2013-2018)
  • Table 86. North America Meropenem, by Country USD Million (2013-2018)
  • Table 87. North America Meropenem, by Application USD Million (2013-2018)
  • Table 88. North America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 89. North America Meropenem, by Strength USD Million (2013-2018)
  • Table 90. United States Meropenem, by Application USD Million (2013-2018)
  • Table 91. United States Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 92. United States Meropenem, by Strength USD Million (2013-2018)
  • Table 93. Canada Meropenem, by Application USD Million (2013-2018)
  • Table 94. Canada Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 95. Canada Meropenem, by Strength USD Million (2013-2018)
  • Table 96. Mexico Meropenem, by Application USD Million (2013-2018)
  • Table 97. Mexico Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 98. Mexico Meropenem, by Strength USD Million (2013-2018)
  • Table 99. Meropenem Sales: by Application(K Units)
  • Table 100. Meropenem Sales Hospital use , by Region K Units (2013-2018)
  • Table 101. Meropenem Sales Clinic , by Region K Units (2013-2018)
  • Table 102. Meropenem Sales Others , by Region K Units (2013-2018)
  • Table 103. Meropenem Sales: by Distribution Channel(K Units)
  • Table 104. Meropenem Sales Online , by Region K Units (2013-2018)
  • Table 105. Meropenem Sales Offline , by Region K Units (2013-2018)
  • Table 106. Meropenem Sales: by Strength(K Units)
  • Table 107. Meropenem Sales 0.5g , by Region K Units (2013-2018)
  • Table 108. Meropenem Sales 1.0g , by Region K Units (2013-2018)
  • Table 109. Meropenem Sales 1.5g , by Region K Units (2013-2018)
  • Table 110. Meropenem Sales 2.0g , by Region K Units (2013-2018)
  • Table 111. South America Meropenem Sales, by Country K Units (2013-2018)
  • Table 112. South America Meropenem Sales, by Application K Units (2013-2018)
  • Table 113. South America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 114. South America Meropenem Sales, by Strength K Units (2013-2018)
  • Table 115. Brazil Meropenem Sales, by Application K Units (2013-2018)
  • Table 116. Brazil Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 117. Brazil Meropenem Sales, by Strength K Units (2013-2018)
  • Table 118. Argentina Meropenem Sales, by Application K Units (2013-2018)
  • Table 119. Argentina Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 120. Argentina Meropenem Sales, by Strength K Units (2013-2018)
  • Table 121. Rest of South America Meropenem Sales, by Application K Units (2013-2018)
  • Table 122. Rest of South America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 123. Rest of South America Meropenem Sales, by Strength K Units (2013-2018)
  • Table 124. Asia Pacific Meropenem Sales, by Country K Units (2013-2018)
  • Table 125. Asia Pacific Meropenem Sales, by Application K Units (2013-2018)
  • Table 126. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 127. Asia Pacific Meropenem Sales, by Strength K Units (2013-2018)
  • Table 128. China Meropenem Sales, by Application K Units (2013-2018)
  • Table 129. China Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 130. China Meropenem Sales, by Strength K Units (2013-2018)
  • Table 131. Japan Meropenem Sales, by Application K Units (2013-2018)
  • Table 132. Japan Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 133. Japan Meropenem Sales, by Strength K Units (2013-2018)
  • Table 134. India Meropenem Sales, by Application K Units (2013-2018)
  • Table 135. India Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 136. India Meropenem Sales, by Strength K Units (2013-2018)
  • Table 137. South Korea Meropenem Sales, by Application K Units (2013-2018)
  • Table 138. South Korea Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 139. South Korea Meropenem Sales, by Strength K Units (2013-2018)
  • Table 140. Taiwan Meropenem Sales, by Application K Units (2013-2018)
  • Table 141. Taiwan Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 142. Taiwan Meropenem Sales, by Strength K Units (2013-2018)
  • Table 143. Australia Meropenem Sales, by Application K Units (2013-2018)
  • Table 144. Australia Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 145. Australia Meropenem Sales, by Strength K Units (2013-2018)
  • Table 146. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2013-2018)
  • Table 147. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 148. Rest of Asia-Pacific Meropenem Sales, by Strength K Units (2013-2018)
  • Table 149. Europe Meropenem Sales, by Country K Units (2013-2018)
  • Table 150. Europe Meropenem Sales, by Application K Units (2013-2018)
  • Table 151. Europe Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 152. Europe Meropenem Sales, by Strength K Units (2013-2018)
  • Table 153. Germany Meropenem Sales, by Application K Units (2013-2018)
  • Table 154. Germany Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 155. Germany Meropenem Sales, by Strength K Units (2013-2018)
  • Table 156. France Meropenem Sales, by Application K Units (2013-2018)
  • Table 157. France Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 158. France Meropenem Sales, by Strength K Units (2013-2018)
  • Table 159. Italy Meropenem Sales, by Application K Units (2013-2018)
  • Table 160. Italy Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 161. Italy Meropenem Sales, by Strength K Units (2013-2018)
  • Table 162. United Kingdom Meropenem Sales, by Application K Units (2013-2018)
  • Table 163. United Kingdom Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 164. United Kingdom Meropenem Sales, by Strength K Units (2013-2018)
  • Table 165. Spain Meropenem Sales, by Application K Units (2013-2018)
  • Table 166. Spain Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 167. Spain Meropenem Sales, by Strength K Units (2013-2018)
  • Table 168. Netherlands Meropenem Sales, by Application K Units (2013-2018)
  • Table 169. Netherlands Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 170. Netherlands Meropenem Sales, by Strength K Units (2013-2018)
  • Table 171. Rest of Europe Meropenem Sales, by Application K Units (2013-2018)
  • Table 172. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 173. Rest of Europe Meropenem Sales, by Strength K Units (2013-2018)
  • Table 174. MEA Meropenem Sales, by Country K Units (2013-2018)
  • Table 175. MEA Meropenem Sales, by Application K Units (2013-2018)
  • Table 176. MEA Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 177. MEA Meropenem Sales, by Strength K Units (2013-2018)
  • Table 178. Middle East Meropenem Sales, by Application K Units (2013-2018)
  • Table 179. Middle East Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 180. Middle East Meropenem Sales, by Strength K Units (2013-2018)
  • Table 181. Africa Meropenem Sales, by Application K Units (2013-2018)
  • Table 182. Africa Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 183. Africa Meropenem Sales, by Strength K Units (2013-2018)
  • Table 184. North America Meropenem Sales, by Country K Units (2013-2018)
  • Table 185. North America Meropenem Sales, by Application K Units (2013-2018)
  • Table 186. North America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 187. North America Meropenem Sales, by Strength K Units (2013-2018)
  • Table 188. United States Meropenem Sales, by Application K Units (2013-2018)
  • Table 189. United States Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 190. United States Meropenem Sales, by Strength K Units (2013-2018)
  • Table 191. Canada Meropenem Sales, by Application K Units (2013-2018)
  • Table 192. Canada Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 193. Canada Meropenem Sales, by Strength K Units (2013-2018)
  • Table 194. Mexico Meropenem Sales, by Application K Units (2013-2018)
  • Table 195. Mexico Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 196. Mexico Meropenem Sales, by Strength K Units (2013-2018)
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Meropenem: by Application(USD Million)
  • Table 209. Meropenem Hospital use , by Region USD Million (2019-2024)
  • Table 210. Meropenem Clinic , by Region USD Million (2019-2024)
  • Table 211. Meropenem Others , by Region USD Million (2019-2024)
  • Table 212. Meropenem: by Distribution Channel(USD Million)
  • Table 213. Meropenem Online , by Region USD Million (2019-2024)
  • Table 214. Meropenem Offline , by Region USD Million (2019-2024)
  • Table 215. Meropenem: by Strength(USD Million)
  • Table 216. Meropenem 0.5g , by Region USD Million (2019-2024)
  • Table 217. Meropenem 1.0g , by Region USD Million (2019-2024)
  • Table 218. Meropenem 1.5g , by Region USD Million (2019-2024)
  • Table 219. Meropenem 2.0g , by Region USD Million (2019-2024)
  • Table 220. South America Meropenem, by Country USD Million (2019-2024)
  • Table 221. South America Meropenem, by Application USD Million (2019-2024)
  • Table 222. South America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 223. South America Meropenem, by Strength USD Million (2019-2024)
  • Table 224. Brazil Meropenem, by Application USD Million (2019-2024)
  • Table 225. Brazil Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 226. Brazil Meropenem, by Strength USD Million (2019-2024)
  • Table 227. Argentina Meropenem, by Application USD Million (2019-2024)
  • Table 228. Argentina Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 229. Argentina Meropenem, by Strength USD Million (2019-2024)
  • Table 230. Rest of South America Meropenem, by Application USD Million (2019-2024)
  • Table 231. Rest of South America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 232. Rest of South America Meropenem, by Strength USD Million (2019-2024)
  • Table 233. Asia Pacific Meropenem, by Country USD Million (2019-2024)
  • Table 234. Asia Pacific Meropenem, by Application USD Million (2019-2024)
  • Table 235. Asia Pacific Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 236. Asia Pacific Meropenem, by Strength USD Million (2019-2024)
  • Table 237. China Meropenem, by Application USD Million (2019-2024)
  • Table 238. China Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 239. China Meropenem, by Strength USD Million (2019-2024)
  • Table 240. Japan Meropenem, by Application USD Million (2019-2024)
  • Table 241. Japan Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 242. Japan Meropenem, by Strength USD Million (2019-2024)
  • Table 243. India Meropenem, by Application USD Million (2019-2024)
  • Table 244. India Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 245. India Meropenem, by Strength USD Million (2019-2024)
  • Table 246. South Korea Meropenem, by Application USD Million (2019-2024)
  • Table 247. South Korea Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 248. South Korea Meropenem, by Strength USD Million (2019-2024)
  • Table 249. Taiwan Meropenem, by Application USD Million (2019-2024)
  • Table 250. Taiwan Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 251. Taiwan Meropenem, by Strength USD Million (2019-2024)
  • Table 252. Australia Meropenem, by Application USD Million (2019-2024)
  • Table 253. Australia Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 254. Australia Meropenem, by Strength USD Million (2019-2024)
  • Table 255. Rest of Asia-Pacific Meropenem, by Application USD Million (2019-2024)
  • Table 256. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 257. Rest of Asia-Pacific Meropenem, by Strength USD Million (2019-2024)
  • Table 258. Europe Meropenem, by Country USD Million (2019-2024)
  • Table 259. Europe Meropenem, by Application USD Million (2019-2024)
  • Table 260. Europe Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 261. Europe Meropenem, by Strength USD Million (2019-2024)
  • Table 262. Germany Meropenem, by Application USD Million (2019-2024)
  • Table 263. Germany Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 264. Germany Meropenem, by Strength USD Million (2019-2024)
  • Table 265. France Meropenem, by Application USD Million (2019-2024)
  • Table 266. France Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 267. France Meropenem, by Strength USD Million (2019-2024)
  • Table 268. Italy Meropenem, by Application USD Million (2019-2024)
  • Table 269. Italy Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 270. Italy Meropenem, by Strength USD Million (2019-2024)
  • Table 271. United Kingdom Meropenem, by Application USD Million (2019-2024)
  • Table 272. United Kingdom Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 273. United Kingdom Meropenem, by Strength USD Million (2019-2024)
  • Table 274. Spain Meropenem, by Application USD Million (2019-2024)
  • Table 275. Spain Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 276. Spain Meropenem, by Strength USD Million (2019-2024)
  • Table 277. Netherlands Meropenem, by Application USD Million (2019-2024)
  • Table 278. Netherlands Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 279. Netherlands Meropenem, by Strength USD Million (2019-2024)
  • Table 280. Rest of Europe Meropenem, by Application USD Million (2019-2024)
  • Table 281. Rest of Europe Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 282. Rest of Europe Meropenem, by Strength USD Million (2019-2024)
  • Table 283. MEA Meropenem, by Country USD Million (2019-2024)
  • Table 284. MEA Meropenem, by Application USD Million (2019-2024)
  • Table 285. MEA Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 286. MEA Meropenem, by Strength USD Million (2019-2024)
  • Table 287. Middle East Meropenem, by Application USD Million (2019-2024)
  • Table 288. Middle East Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 289. Middle East Meropenem, by Strength USD Million (2019-2024)
  • Table 290. Africa Meropenem, by Application USD Million (2019-2024)
  • Table 291. Africa Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 292. Africa Meropenem, by Strength USD Million (2019-2024)
  • Table 293. North America Meropenem, by Country USD Million (2019-2024)
  • Table 294. North America Meropenem, by Application USD Million (2019-2024)
  • Table 295. North America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 296. North America Meropenem, by Strength USD Million (2019-2024)
  • Table 297. United States Meropenem, by Application USD Million (2019-2024)
  • Table 298. United States Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 299. United States Meropenem, by Strength USD Million (2019-2024)
  • Table 300. Canada Meropenem, by Application USD Million (2019-2024)
  • Table 301. Canada Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 302. Canada Meropenem, by Strength USD Million (2019-2024)
  • Table 303. Mexico Meropenem, by Application USD Million (2019-2024)
  • Table 304. Mexico Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 305. Mexico Meropenem, by Strength USD Million (2019-2024)
  • Table 306. Meropenem Sales: by Application(K Units)
  • Table 307. Meropenem Sales Hospital use , by Region K Units (2019-2024)
  • Table 308. Meropenem Sales Clinic , by Region K Units (2019-2024)
  • Table 309. Meropenem Sales Others , by Region K Units (2019-2024)
  • Table 310. Meropenem Sales: by Distribution Channel(K Units)
  • Table 311. Meropenem Sales Online , by Region K Units (2019-2024)
  • Table 312. Meropenem Sales Offline , by Region K Units (2019-2024)
  • Table 313. Meropenem Sales: by Strength(K Units)
  • Table 314. Meropenem Sales 0.5g , by Region K Units (2019-2024)
  • Table 315. Meropenem Sales 1.0g , by Region K Units (2019-2024)
  • Table 316. Meropenem Sales 1.5g , by Region K Units (2019-2024)
  • Table 317. Meropenem Sales 2.0g , by Region K Units (2019-2024)
  • Table 318. South America Meropenem Sales, by Country K Units (2019-2024)
  • Table 319. South America Meropenem Sales, by Application K Units (2019-2024)
  • Table 320. South America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 321. South America Meropenem Sales, by Strength K Units (2019-2024)
  • Table 322. Brazil Meropenem Sales, by Application K Units (2019-2024)
  • Table 323. Brazil Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 324. Brazil Meropenem Sales, by Strength K Units (2019-2024)
  • Table 325. Argentina Meropenem Sales, by Application K Units (2019-2024)
  • Table 326. Argentina Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 327. Argentina Meropenem Sales, by Strength K Units (2019-2024)
  • Table 328. Rest of South America Meropenem Sales, by Application K Units (2019-2024)
  • Table 329. Rest of South America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 330. Rest of South America Meropenem Sales, by Strength K Units (2019-2024)
  • Table 331. Asia Pacific Meropenem Sales, by Country K Units (2019-2024)
  • Table 332. Asia Pacific Meropenem Sales, by Application K Units (2019-2024)
  • Table 333. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 334. Asia Pacific Meropenem Sales, by Strength K Units (2019-2024)
  • Table 335. China Meropenem Sales, by Application K Units (2019-2024)
  • Table 336. China Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 337. China Meropenem Sales, by Strength K Units (2019-2024)
  • Table 338. Japan Meropenem Sales, by Application K Units (2019-2024)
  • Table 339. Japan Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 340. Japan Meropenem Sales, by Strength K Units (2019-2024)
  • Table 341. India Meropenem Sales, by Application K Units (2019-2024)
  • Table 342. India Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 343. India Meropenem Sales, by Strength K Units (2019-2024)
  • Table 344. South Korea Meropenem Sales, by Application K Units (2019-2024)
  • Table 345. South Korea Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 346. South Korea Meropenem Sales, by Strength K Units (2019-2024)
  • Table 347. Taiwan Meropenem Sales, by Application K Units (2019-2024)
  • Table 348. Taiwan Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 349. Taiwan Meropenem Sales, by Strength K Units (2019-2024)
  • Table 350. Australia Meropenem Sales, by Application K Units (2019-2024)
  • Table 351. Australia Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 352. Australia Meropenem Sales, by Strength K Units (2019-2024)
  • Table 353. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2019-2024)
  • Table 354. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 355. Rest of Asia-Pacific Meropenem Sales, by Strength K Units (2019-2024)
  • Table 356. Europe Meropenem Sales, by Country K Units (2019-2024)
  • Table 357. Europe Meropenem Sales, by Application K Units (2019-2024)
  • Table 358. Europe Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 359. Europe Meropenem Sales, by Strength K Units (2019-2024)
  • Table 360. Germany Meropenem Sales, by Application K Units (2019-2024)
  • Table 361. Germany Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 362. Germany Meropenem Sales, by Strength K Units (2019-2024)
  • Table 363. France Meropenem Sales, by Application K Units (2019-2024)
  • Table 364. France Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 365. France Meropenem Sales, by Strength K Units (2019-2024)
  • Table 366. Italy Meropenem Sales, by Application K Units (2019-2024)
  • Table 367. Italy Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 368. Italy Meropenem Sales, by Strength K Units (2019-2024)
  • Table 369. United Kingdom Meropenem Sales, by Application K Units (2019-2024)
  • Table 370. United Kingdom Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 371. United Kingdom Meropenem Sales, by Strength K Units (2019-2024)
  • Table 372. Spain Meropenem Sales, by Application K Units (2019-2024)
  • Table 373. Spain Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 374. Spain Meropenem Sales, by Strength K Units (2019-2024)
  • Table 375. Netherlands Meropenem Sales, by Application K Units (2019-2024)
  • Table 376. Netherlands Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 377. Netherlands Meropenem Sales, by Strength K Units (2019-2024)
  • Table 378. Rest of Europe Meropenem Sales, by Application K Units (2019-2024)
  • Table 379. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 380. Rest of Europe Meropenem Sales, by Strength K Units (2019-2024)
  • Table 381. MEA Meropenem Sales, by Country K Units (2019-2024)
  • Table 382. MEA Meropenem Sales, by Application K Units (2019-2024)
  • Table 383. MEA Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 384. MEA Meropenem Sales, by Strength K Units (2019-2024)
  • Table 385. Middle East Meropenem Sales, by Application K Units (2019-2024)
  • Table 386. Middle East Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 387. Middle East Meropenem Sales, by Strength K Units (2019-2024)
  • Table 388. Africa Meropenem Sales, by Application K Units (2019-2024)
  • Table 389. Africa Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 390. Africa Meropenem Sales, by Strength K Units (2019-2024)
  • Table 391. North America Meropenem Sales, by Country K Units (2019-2024)
  • Table 392. North America Meropenem Sales, by Application K Units (2019-2024)
  • Table 393. North America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 394. North America Meropenem Sales, by Strength K Units (2019-2024)
  • Table 395. United States Meropenem Sales, by Application K Units (2019-2024)
  • Table 396. United States Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 397. United States Meropenem Sales, by Strength K Units (2019-2024)
  • Table 398. Canada Meropenem Sales, by Application K Units (2019-2024)
  • Table 399. Canada Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 400. Canada Meropenem Sales, by Strength K Units (2019-2024)
  • Table 401. Mexico Meropenem Sales, by Application K Units (2019-2024)
  • Table 402. Mexico Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 403. Mexico Meropenem Sales, by Strength K Units (2019-2024)
  • Table 404. Research Programs/Design for This Report
  • Table 405. Key Data Information from Secondary Sources
  • Table 406. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meropenem: by Application USD Million (2013-2018)
  • Figure 5. Global Meropenem: by Distribution Channel USD Million (2013-2018)
  • Figure 6. Global Meropenem: by Strength USD Million (2013-2018)
  • Figure 7. South America Meropenem Share (%), by Country
  • Figure 8. Asia Pacific Meropenem Share (%), by Country
  • Figure 9. Europe Meropenem Share (%), by Country
  • Figure 10. MEA Meropenem Share (%), by Country
  • Figure 11. North America Meropenem Share (%), by Country
  • Figure 12. Global Meropenem: by Application K Units (2013-2018)
  • Figure 13. Global Meropenem: by Distribution Channel K Units (2013-2018)
  • Figure 14. Global Meropenem: by Strength K Units (2013-2018)
  • Figure 15. South America Meropenem Share (%), by Country
  • Figure 16. Asia Pacific Meropenem Share (%), by Country
  • Figure 17. Europe Meropenem Share (%), by Country
  • Figure 18. MEA Meropenem Share (%), by Country
  • Figure 19. North America Meropenem Share (%), by Country
  • Figure 20. Global Meropenem share by Players 2018 (%)
  • Figure 21. Global Meropenem share by Players (Top 3) 2018(%)
  • Figure 22. Global Meropenem share by Players (Top 5) 2018(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2018
  • Figure 26. Shenzhen Haibin Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 27. Shenzhen Haibin Pharmaceutical (China) Revenue: by Geography 2018
  • Figure 28. Fresenius Kabi (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Fresenius Kabi (Canada) Revenue: by Geography 2018
  • Figure 30. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 32. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 33. Mylan (United States) Revenue: by Geography 2018
  • Figure 34. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takeda (Japan) Revenue: by Geography 2018
  • Figure 36. Sumitomo Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Sumitomo Pharmaceuticals (Japan) Revenue: by Geography 2018
  • Figure 38. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue: by Geography 2018
  • Figure 40. Astra Zeneca Pharma (India) Revenue, Net Income and Gross profit
  • Figure 41. Astra Zeneca Pharma (India) Revenue: by Geography 2018
  • Figure 42. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 43. Abbott (United States) Revenue: by Geography 2018
  • Figure 44. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 45. GE Healthcare (United States) Revenue: by Geography 2018
  • Figure 46. Global Meropenem: by Application USD Million (2019-2024)
  • Figure 47. Global Meropenem: by Distribution Channel USD Million (2019-2024)
  • Figure 48. Global Meropenem: by Strength USD Million (2019-2024)
  • Figure 49. South America Meropenem Share (%), by Country
  • Figure 50. Asia Pacific Meropenem Share (%), by Country
  • Figure 51. Europe Meropenem Share (%), by Country
  • Figure 52. MEA Meropenem Share (%), by Country
  • Figure 53. North America Meropenem Share (%), by Country
  • Figure 54. Global Meropenem: by Application K Units (2019-2024)
  • Figure 55. Global Meropenem: by Distribution Channel K Units (2019-2024)
  • Figure 56. Global Meropenem: by Strength K Units (2019-2024)
  • Figure 57. South America Meropenem Share (%), by Country
  • Figure 58. Asia Pacific Meropenem Share (%), by Country
  • Figure 59. Europe Meropenem Share (%), by Country
  • Figure 60. MEA Meropenem Share (%), by Country
  • Figure 61. North America Meropenem Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Shenzhen Haibin Pharmaceutical (China)
  • Fresenius Kabi (Canada)
  • Novartis (Switzerland)
  • Mylan (United States)
  • Takeda (Japan)
  • Sumitomo Pharmaceuticals (Japan)
  • Sumitomo Dainippon Pharma Co. Ltd. (Japan)
  • Astra Zeneca Pharma (India)
  • Abbott (United States)
  • GE Healthcare (United States)
Additional players considered in the study are as follows:
Spectrum Chemical Manufacturing Corp (United States) , Shijiazhuang Pharma (China) , Haikou Pharmaceutical Factory (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation